Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer

Advances in Experimental Medicine and Biology

Volumn 640, Issue , 2008, Pages 220-233

  Nakamura, Akira ^a   Kubo, Tomohiro ^b   Takai, Toshiyuki ^b  

^a TOHOKU UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BISPECIFIC ANTIBODY; FC ALPHA RECEPTOR I; FC EPSILON RECEPTOR I; FC EPSILON RECEPTOR II; FC MU RECEPTOR; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IIIA; FC RECEPTOR IIIB; FC RECEPTOR IV; IMMUNOGLOBULIN; INFLIXIMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; RECOMBINANT PROTEIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

AGAMMAGLOBULINEMIA; ALLERGIC RHINITIS; ALLERGY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; ASTHMA; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CLINICAL TRIAL; DENDRITIC CELL; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN DEFICIENCY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; ANIMAL; CHEMISTRY; HYPERSENSITIVITY; IMMUNOLOGY; NEOPLASM;

MURINAE;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; HYPERSENSITIVITY; NEOPLASMS; RECEPTORS, FC;

EID: 58149360480     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-09789-3_17     Document Type: Review

References (94)

1. Heyman B. Regulation of antibody responses via antibodies, complement and Fc receptors. Annu Rev Immunol 2000; 18:709-737.
2. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-290.
3. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002; 2:580-592.
4. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 2002; 14:798-802.
5. Nimmerjahn F, Ravetch JV. Feγ receptors: Old friends and new family members. Immunity 2006; 24:19-28.
6. Nimmerjahn F, Bruhns P, Horiuchi K et al. FcγRIV: A novel FcR with distinct IgG subclass specificity. Immunity 2005; 23:41-51.
7. Roopenian DC, Christianson GJ, Sproule TJ et al. The MHO class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003; 170:3528-3233.
8. Sondermann P, Huber R, Oosthuizen V et al. The 3.2-Å crystal structure of the human IgGl Fc fragment-FcγRIII complex. Nature 2000; 406:267-273.
9. Garman SC, Wiirzburg BA, Tarchevskaya SS et al. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα. Nature 2000; 406:259-266.
10. Herr AB, Ballister ER, Bjorkman PJ. Insights into IgA-mediated immune responses from the crystal structures of human FcαRI and its complex with IgAl-Fc. Nature 2003; 423:614-620.
11. Radaev S, Motyka S, Fridman W H et al. The structure of a human type III Feγ receptor in complex with Fc. J Biol Chem 2001; 276:16469-16477.
12. Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004; 4:89-99.
13. Maxwell KF, Powell MS, Hulett MD et al. Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nat Struct Biol 1999; 6:437-442.
14. Sondermann P, Huber R, Jacob U. Crystal structure of the soluble form of the human Fcγ-receptor lib: A new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J 1999; 18:1095-1103.
15. Garman SC, Kinet JP, Jardetzky TS. Crystal structure of the human high-affinity IgE receptor. Cell 1998; 95:951-961.
16. Ding Y, Xu G, Yang M et al. Crystal structure of the ectodomain of human FcaRI. J Biol Chem 2003; 278:27966-27970.
17. Willcox BE, Thomas LM, Bjorkman PJ. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor Nat Immunol 2003; 4:913-919.
18. Chapman TL, Heikema AP, West AP Jr et al. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2) Immunity 2000; 13:727-736.
19. Ghazizadeh S, Bolen JB, Fleit HB. Physical and functional association of Src-related protein tyrosine kinases with FcγRII in monocytic THP-1 cells. J Biol Chem 1994; 269:8878-8884.
20. Wang AV, Scholl PR, Geha RS. Physical and functional association of the high affinity immunoglobulin G receptor (FcγRI) with the kinases Hck and Lyn. J Exp Med 1994; 180:1165-1170.
21. Bolland S, Pearse RN, Kurosaki T et al. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 1998; 8:509-516.
22. 2+ following B-cell receptor activation. EMBO J 1998; 17:1973-1985.
23. Tamir I, Stolpa JC, Helgason CD et al. The RasGAP-binding protein p62dok is a mediator of inhibitory FcγRIIB signals in B-cells. Immunity 2000; 12:347-358.
24. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995; 182:1609-1614.
25. Clynes R, Takechi Y, Moroi Y et al. Fc receptors are required in passive and active immunity to melanoma. Proc Nad Acad Sci USA 1998; 95:652-656.
26. Clynes RA, Towers TL, Presta LG et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-446.
27. Akiyama K, Ebihara S, Yada A et al. Targeting apoptotic tumor cells to FcγR provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 2003; 170:1641-1648.
28. Yada A, Ebihara S, Matsumura K et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FcγRIIB- and FcγRI/III-mediated immune complex uptake. Cell Immunol 2003; 225:21-32.
29. Regnault A, Lankar D, Lacabanne V et al. Feγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune comple internalization. J Exp Med 1999; 189:371-380.
30. Rodriguez A, Regnault A, Kleijmeer M et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1:362-368.
31. Dhodapkar KM, Krasovsky J, Williamson B et al. Antitumor monoclonal antibodies enhance cross-presentation of cCellular antigens and the generation of myeloma-specific killer T-cells by dendritic cells. J Exp Med 2002; 195:125-133.
32. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Feγ receptors on dendritic cells. J Exp Med 2002; 195:1653-1659.
33. Bergtold A, Desai DD, Gavhane A et al. Cell surface recycling of internalized antigen permits dendritic cell priming of B-cells. Immunity 2005; 23:503-514.
34. Sinclair NR. Fc-signaUing in the modulation of immune responses by passive antibody. Scand J Immunol 2001; 53:322-330.
35. Nakamura A, Akiyama K, Takai T. Fc receptor targeting in the treatment of allergy, autoimmune disease and cancer. Expert Opin Ther Targets 2005; 9:169-190.
36. Kinet JR Atopic allergy and other hypersensitivities. Curr Opin Immunol 1999; 11: 603-605.
37. Weinberger M. Innovative therapies for asthma: anti-IgE-The future? Paediatr Respir Rev 2004; 5 SupplA:S115-118.
38. Busse W, Neaville W Anti-immunoglobulin E for the treatment of allergic disease. Curr Opin Allergy Clin Immunol 2001; 1:105-108.
39. Bruhns P, Fremont S, Daeron M. Regulation of allergy by Fc receptors. Curr Opin Immunol 2005; 17:662-669.
40. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354:2689-2695.
41. Goodnow CC. Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet 2001; 357:2115-2121.
42. Scofield RH. Autoantibodies as predictors of disease. Lancet 2004; 363:1544-1546.
43. Olseni NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350:2167-2179.
44. Choy EH, Isenberg DA, Garrood T et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46:3143-3150.
45. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50:1761-1769.
46. Gorman C, Leandro M, Isenberg D. B-cell depletion in autoimmune disease. Arthritis Res Ther 2003; 5:S17-21.
47. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
48. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006; 6:859-866.
49. Coiffier B. Monoclonal antibody as therapy for malignant lymphomas. CR Biol 2006; 329:241-254.
50. Gopal AK, Press OW Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999; 134:445-450.
51. Uchida J, Hamaguchi Y, Oliver JA et al. The innate mononuclear phagocyte network depletes B-lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-6169.
52. Anohk JH, Campbell D, Felgar RE et al. The relationship of FcyRIIIa genotype to degree of B-cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48:455-459.
53. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947.
54. Glennie MJ, Johnson PW Chnical trials of antibody therapy. Immunol. Today 2000; 21:403-410.
55. Gelderman KA, Tomlinson S, Ross GD et al. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004; 25:158-164.
56. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5:292-302.
57. Anderson KG, Bates MP, Slaughenhoupt BL et al. Expression of human B-cell-associated antigens on leukemias and lymphomas: A model of human B-cell differentiation. Blood 1984; 63:1424-1433.
58. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-GD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99:754-758.
59. Zhang Z, Zhang M, Goldman CK et aL Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-GD52 monoclonal antibody, Gampath-IH. Cancer Res 2003; 63:6453-6457.
60. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
61. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 2004; 14:262-270.
62. Sliwkowski MX, Lofgren JA, Lewis GD et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 4 Suppl 12:60-70.
63. zum Buschenfelde CM, Hermann C, Schmidt B et al. Antihuman epidermal growth factor receptor 2 {HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T-lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002; 62: 2244-2247.
64. Kono K, Sato E, Naganuma H et al. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res 2004; 10:2538-2544.
65. Bolland S, Ravetch JV. Spontaneous autoimmune disease in FeγRIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13:277-285.
66. Yajima K, Nakamura A, Sugahara A et al. FcγRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease. Eur J Immimol 2003; 33:1020-1029.
67. Kyogoku C, Dijstelbloem HM, Tsuchiya N et al. Feγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46:1242-1254.
68. Siriboonrit U, Tsuchiya N, Sirikong M et al. Association of Fey receptor lib and Illb polymorphisms with susceptibility to systemic lupus erythematosus in Thais. Tissue Antigens 2003; 61:374-383.
69. Floto RA, Clatworthy MR, Heilbronn KR et al. Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafi Nat Med 2005; 11:1056-1058.
70. Kono H, Kyogoku C, Suzuki T et al. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafi:s and attenuates inhibitory effects on B-cell receptor signaling. Hum Mol Genet 2005; 14:2881-2892.
71. Zhu D, Kepley CL, Zhang M et al. A novel himian immunoglobulin Fcy-Fce bifunctional fusion protein inhibits FceRI-mediated degranulation. Nat Med 2002; 8:518-521.
72. Zhu D, Kepley CL, Zhang K et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11:446-449.
73. Tam SW, Demissie S, Thomas D et al. A bispecific antibody against human IgE and human Fcgamma- RII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 2004; 59:772-780.
74. Rankin CT, Veri MC, Gorlatov S et al. CD32B, the human inhibitory Feγ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 2006; 108:2384-2391.
75. Cines DB, Blanchettei VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995-1008.
76. Yuki N. Infectious origins of and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 2001; 1:29-37.
77. Durelli L, Isoardo G. High-dose intravenous immunoglobulin treatment of multiple sclerosis. Neurol Sci 2002; 23:S39-48.
78. Latov N, Chaudhry V, Koski CL et al. Use of intravenous y globulins in neuroimmunologic diseases. J Allergy Clin Immunol 2001; 108:S126-132.
79. Wiles CM, Brown P, Chapel H et al. Intravenous immunoglobulin in neurological disease: A specialist review. J Neurol Neurosurg Psychiatry 2002; 72:440-448.
80. Burns JC. Kawasaki disease. Adv Pediatr 2001; 48:157-177.
81. Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002; 107:387-393.
82. Simon HU, Spath PJ. IVIG-Mechanisms of action. Allergy 2003; 58:543-552.
83. Bayry J, Thirion M, Misra N et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol 2003; 10:165-169.
84. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-486.
85. Kaneko Y, Nimmerjahn F, Madaio MP et al. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006; 203:789-797.
86. Bruhns P, Samuelsson A, Pollard JW et al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18:573-581.
87. Crow AR, Song S, Freedman J et al. IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIPl, SHP-1 and Btk activity. Blood 2003; 102:558-560.
88. Siragam V, Crow AR, Brine D et al. Intravenous immunoglobulin ameliorates ITP via activating Feγ receptors on dendritic cells. Nat Med 2006; 12:688-692.
89. Akilesh S, Petkova S, Sproule TJ et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 2004; 113:1328-1333.
90. Li N, Zhao M, Hilario-Vargas J et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005; 115:3440-3450.
91. McDonnell JM, Beavil AJ, Mackay GA et al. Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor. Nat Struct Biol 1996; 5:419-426.
92. Marino M, Ruvo M, De Falco S et al. Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nat Biotechnol 2000; 18:735-739.
93. Uray K, Medgyesi D, Hilbert A et al. Synthesis and receptor binding of IgGl peptides derived from the IgG Fc region. J Mol Recognit 2004; 17:95-105.
94. Medgyesi D, Uray K, Sallai K et al. Functional mapping of the FcγRII binding site on human IgGl by synthetic peptides. Eur J Immunol 2004; 34:1127-1135.